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Abstract—  7-([(2Z)- 2-(2-amino- 1,3-thiazol- 4-yl)- 2-
methoxyiminoacetyl]amino)- 8-oxo- 3[(2S)-oxolan- 2-yl]- 5-
thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
(cefovecin) is an antibiotic of the cephalosporin class . In 
silico binding free energy of six analogous structurally 
diverse cefovecin with Pseudomonas aeruginosa lipase were 
determined using Patchdock and Firedock  softwares. The 
bonding interactions were also studied. The binding energy 
of cefovecin was -44.30 kcal/mol. The free binding energies 
of COOH, COCH3, CH3, NO2, CF3 and NH2 analogues were 
-44.30, -43.55, -39.49, -43.40,   -30.25 and -44.18 Kcal/mol 
respectively. All the monosubstituted analogues showed 
lower negative values than the non substituted cefovecin. 
These lower negative values indicate that that the reactions 
are feasible. Their inhibition is lower compared to cefovecin 
against Pseudomonas aeruginosa lipase. The modes of 
bonding of six analogous structurally diverse cefovecin with 
Pseudomonas aeruginosa lipase were attributed to hydrogen 
bonding and steric interaction.  
Keywords— Binding energy, cefovecin, docking, 
Pseudomonas aeruginosa lipase, scoring function  
 
I. INTRODUCTION 
Cefovecin is an antibiotic of the cephalosporin class, licensed 
for the treatment of skin infections in cat and dogs. It is the 
first single-dose injectable antibiotic for dogs and cats that 
assures owner compliance with dosing for the animal. It is 
used for the treatment of skin infections caused by Pasturella 
multocida in cats, and Staphylococcus intermedius/S. canis 
in dogs. The advantage of using injectable antibiotics is not 
missing a dose that can allow partially resistant microbes to 
recover during missed doses. The disadvantage is the durable 
presence of subtherapeutic concentrations in the weeks after 
the resolution of infections. This is associated with the 
development of resistance in microbes. It is effective, but 
should not be used in pregnant or lactating animals or in 
animals with a history of allergies to penicillin or 
cephalosporin drugs [1]. Cefovecin was first authorized for 
use in the European Union in June 2006 [2], and was 
approved for use in the United States in June 2008 [3]. It is 
approved as a broad-spectrum, third-generation 
cephalosporin for subcutaneous injection lasting 14 days for 
treating skin and soft tissue infections [4]. Contraindications 
include known allergies to cefovecin or antibiotics 
containing β-lactam rings such as penicillin or 
cephalosporins. Adverse reactions can include anaphylaxis. 
It is not for use in humans and should be kept out of reach of 
children. Individuals with similar known allergies should 
avoid dermal contact when handling the drugs. Adverse 
reactions in dogs can include lethargy, decreased appetite, 
vomiting, diarrhea, blood in feces, and flatulence. Adverse 
reactions in cats can include vomiting, diarrhea, decreased 
appetite, lethargy, odd hyperactive behavior, and 
inappropriate urination. Mildly increased serum ALT and 
gamma glutamyl transferase have been noted [5]. The 
following adverse events were reported voluntarily during 
post-approval use of the product in dogs and cats: death, 
tremors/ataxia, seizures, anaphylaxis, acute pulmonary 
edema, facial edema, injection site reactions (alopecia, scabs, 
necrosis, and erythema), hemolytic anemia, salivation, 
pruritis, lethargy, vomiting, diarrhea, and inappetance [6]. 
Cefovecin functions by interfering with cell wall synthesis. 
The chemical covalently binds to the so-called pencillin  
binding proteins. Due to the high protein-binding of the 
chemical, it is not effective against Pseudomonas spp., or 
enterococci. In drug studies, cefovecin administered to dogs 
International Journal of Advanced Engineering, Management and Science (IJAEMS)                             [Vol-3, Issue-3, Mar- 2017] 
https://dx.doi.org/10.24001/ijaems.3.3.14                                                                                                                         ISSN: 2454-1311 
www.ijaems.com                                                                                                                                                                          Page | 234 
was 92.4% effective against skin infections (secondary 
superficial pyoderma,abscesses, and infected wounds). In 
cats, it was 96.8% effective against skin infections [7]. Figure 
1 shows the structure of cefovecin. 
 
Fig .1: S tructure  o f -7 -( [( 2Z) - 2 -( 2 -amino - 1 ,3 -
th iazo l- 4 -yl )- 2 -methoxyiminoacetyl]amino) - 8 -oxo- 
3 -[( 2S)-oxo lan - 2 -yl]- 5 -thia- 1 -azabicyclo[4.2.0]oct- 
2 -ene- 2 -carboxyl ic acid[ ( cefovecin )  
 
II. METHODOLOGY 
Protein preparation  
The crystal structure of Pseudomonas aeruginosa lipase was 
obtained from the Protein Data Bank, PDB 1ex9 (Figure 2). 
The protein structure was subjected to a refinement protocol 
using Molegro Molecular Viewer [8].  
 
Designing of structural analogs of Cefovecin 
The structure of cefovecin (Figure 1) was drawn with 
ACD/ChemSketch software [9]. The structural analogues of 
cefovecin were developed with structural modifications with 
different substituents. The carboxylic group [COOH] group 
at of cefovecin was replaced with COCH3, CH3, NO2, CF3 
and NH2 analogues. The structures were built with 
ACD/ChemSketch software and minimized with Arguslab 
software [10].  
 
Molecular docking  
Molecular docking was performed using Patchdock [11]. 
Patchdock is a molecular docking algorithm based on shape 
complementarity principles. Refinement was done in 
Firedock  [12, 13] and processed with Molegro molecular 
viewer [14]. Lipinski rule of 5 was evaluated using 
Sanjeevini: a freely accessible web-server for target directed 
lead molecule discovery [15].  
 
III. RESULTS  AND DISCUSSION 
The Table 1: Estimated free energy of binding (FEB) of 
cefovecin and its analogues against Pseudomonas 
aeruginosa lipase is shown in Table 1. Crystal structure of 
Pseudomonas aeruginosa lipase PDB 1ex9 is shown in 
Figure 2. Cefovecin analogues  in complex with 
Pseudomonas aeruginosa lipase are presented in Figures  3 – 
8. The bonding interactions are illusstrated in Figures  9 – 14. 
 
Fig.2: Crystal structure of Pseudomonas aeruginosa lipase 
PDB 1ex9 
 
 
Fig.3: Cefovecin in complex with Pseudomonas aeruginosa 
lipase 
 
 
Fig.4: Cefovecin COCH3 analogue in complex with 
Pseudomonas aeruginosa lipase 
 
 
Fig.5: Cefovecin CH3 analogue in complex with 
Pseudomonas aeruginosa lipase 
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Fig.6: Cefovecin NO2 analogue in complex with 
Pseudomonas aeruginosa lipase 
 
 
Fig.7: Cefovecin CF3 analogue in complex with 
Pseudomonas aeruginosa lipase 
 
 
Fig.8:  Cefovecin NH2 analogue in complex with 
Pseudomonas aeruginosa lipase 
 
 
Fig.9: Steric interaction of Cefovecin  with Pseudomonas 
aeruginosa lipase 
 
 
Fig.10: Steric interaction of Cefovecin COCH3 analogue 
with Pseudomonas aeruginosa lipase 
 
 
Fig.11: Steric interaction of Cefovecin CH3 analogue with 
Pseudomonas aeruginosa lipase 
 
 
Fig.12: Steric interaction of Cefovecin NO2 analogue with 
Pseudomonas aeruginosa lipase 
 
 
Fig.13: Steric interaction of Cefovecin CF3 analogue with 
Pseudomonas aeruginosa lipase 
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Fig 14: Hydrogen and steric interactions of cefovecin NH2 analogue with Pseudomonas aeruginosa lipase 
Table.1: Estimated free energy of binding (FEB) of cefovecin and its analogues against Pseudomonas aeruginosa lipase 
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To Estimated free energy of binding (FEB) of cefovecin 
and its analogues is shown in Table 1. Crystal structure of 
Pseudomonas aeruginosa lipase is shown in Figure 2. 
Cefovecin in complex with Pseudomonas aeruginosa 
lipase is shown in Figure 3 while the docked cefovecin 
analogues with Pseudomonas aeruginosa lipase are 
presented in Figures 4 – 8. The Hydrogen bonding, 
electrostatic and steric interactions are depicted in Figures 
9 -14. The binding energy of Cefovecin was -44.30 
kcal/mol. The free binding energies  of COCH3,CH3 ,NO2, 
CF3 and NH2 analogues were  -43.55, -39.49, -43.40, -
30.25 and -44.18 Kcal/mol respectively. All the 
monosubstituted analogues showed lower negative values 
than the non substituted cefovecin. These lower negative 
values indicate that their inhibition is lower compared to 
than cefovecin against Pseudomonas aeruginosa lipase. 
The modes of bonding of six analogous structurally diverse 
cefovecin with Pseudomonas aeruginosa lipase were 
attributed to hydrogen bonding and steric interactions. 
Cefovecin and its monosubstituted analogues bonded to 
Pseudomonas aeruginosa lipase through Ser 211, Phe 19, 
Ile 142, Leu 138, Phe 214, Pro 210, Leu 118, Thr 114, Ser 
218, Ala 217, Thr 221, and Phe 117. 
 
IV. CONCLUSION 
The in silico binding energy of cefovecin and its analogues 
with Pseudomonas aeruginosa lipase showed that the 
reactions are feasible because of their negative values of 
free energy. The ability of these drugs to inhibit 
Pseudomonas aeruginosa lipase is assured. We therefore 
recommend the synthesis, characterization and clinical 
studies of these cefovecin derivatives.   
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